The Iliac/SFA/Popliteal Center

Filter Your Results




TRANSCEND Pivotal Clinical Trial Commences for Surmodics' SurVeil DCB

November 2, 2017 -- Surmodics, Inc. announced enrollment of the first patient in TRANSCEND, the pivotal clinical trial for the company's SurVeil drug-coated balloon (DCB).…

Data Published for Medtronic's In.Pact Admiral DCB in De Novo In-Stent Restenosis

October 18, 2017 -- Findings from the IN.PACT Global study's de novo in-stent restenosis (ISR) imaging cohort were published by Marianne Brodmann, MD, et al in Journal of …

Treating Peripheral Artery Disease in the Popliteal Artery: DA + DCB Versus DCB Alone

Konstantinos Stavroulakis, MD

October 2017—The popliteal artery is a known area of high mechanical stress and dynamic force that has been associated with accelerated restenosis and high rates of stent fracture and occl…

Case Study: Complex Long Lesion Intervention With the Lutonix® 035 Drug-Coated Balloon

Robert E. Beasley, MD

October 2017—Choosing the right DCB is paramount to avoiding complications when patients present with nonhealing wounds and single-vessel runoff.

MAJESTIC 3-Year Data Published for Boston Scientific's Eluvia DES

October 11, 2017 -- The 3-year results of the MAJESTIC first-in-human study of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) for treating femoropopli…

The State of Peripheral Drug‑Eluting Technologies

Michael R. Jaff, DO

September 2017— When comparing the myriad options available for the treatment of patients with peripheral artery disease (PAD) today compared to just 1 decade ago, it is a testimony to ph…

Interim Results From the Muenster Postmarket All-Comers Registry

Theodosios Bisdas, MD, PhD

September 2017—A look at the latest data on use of the Eluvia drug-eluting stent in challenging SFA lesions.

Twelve-Month Results From the RANGER-SFA Trial

With Dierk Scheinert, MD

September 2017—What these findings tell us about the safety and efficacy of the Ranger drug-coated balloon.




Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.